Hematology/Oncology · Vineland, NJ
NPI
1750372686
Since 2005
Specialty
Hematology/Oncology
Code 174400000X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
1505 W Sherman Ave, Suite 101
Vineland, NJ, 08360
Phone (856) 696-9550
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.3M
169,817 services
Medicare patients, 2024
510
Average age 74
Drug cost, 2024
$4.1M
1,092 prescriptions
Company payments, 2025
$2,822
From 48 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kush Sachdeva was code J1439 (injection, ferric carboxymaltose, 1 mg), 63,750 times for 54 patients. In total Kush Sachdeva billed 169,817 services in 109 codes, and Medicare paid $2.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-09-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 63,750 | 54 | $0.87 | $55K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 11,200 | 19 | $44.85 | $502K |
| J0897 Injection, denosumab, 1 mg | Office | 5,700 | 30 | $20.55 | $117K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 4,884 | 18 | $20.94 | $102K |
| J9267 Injection, paclitaxel, 1 mg | Office | 4,744 | 12 | $0.08 | $375 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,840 | 23 | $6.24 | $18K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,660 | 17 | $5.80 | $15K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,860 | 57 | $0.09 | $168 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,380 | 26 | $0.07 | $101 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,100 | 34 | $0.70 | $767 |
| 85025 Blood Count | Office | 910 | 265 | $7.61 | $6,925 |
| 99214 Office E&M - Established | Office | 559 | 230 | $104.78 | $59K |
| 99213 Office E&M - Established | Office | 499 | 234 | $78.10 | $39K |
| 96375 Injection Administration | Office | 441 | 71 | $13.77 | $6,074 |
| 96372 Injection Administration | Office | 429 | 112 | $12.58 | $5,397 |
By year: 2022 $2.0M for 124,662 services; 2023 $1.8M for 114,416 services; 2024 $2.3M for 169,817 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 910 | 265 | $7.61 | $6,925 |
| 80053 Clinical Chemistry | 32 | 19 | $10.35 | $331 |
Medicare prescription drug claims, 2024
In 2024, the drug Kush Sachdeva prescribed most often to Medicare patients was Procrit (Epoetin Alfa), with 93 prescriptions and refills. In total Kush Sachdeva wrote 1,092 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Procrit Epoetin Alfa | 93 | 97 | 15 | $223K |
| Letrozole Generic | 61 | 141 | 21 | $1,487 |
| Neulasta Pegfilgrastim | 50 | 50 | 11 | $399K |
| Keytruda Pembrolizumab | 49 | 49 | Under 11 | $540K |
| Xgeva Denosumab | 47 | 47 | Under 11 | $145K |
| Dexamethasone Sodium Phosphate Generic | 42 | 42 | 11 | $52.82 |
| Prednisone Generic | 31 | 31 | 13 | $197 |
| Eliquis Apixaban | 29 | 60 | Under 11 | $33K |
| Dexamethasone Generic | 29 | 33 | 13 | $467 |
| Hydroxyurea Generic | 25 | 55 | Under 11 | $392 |
| Omeprazole Generic | 24 | 34 | 12 | $200 |
| Oxycodone Hcl Generic | 23 | 23 | 13 | $568 |
| Ondansetron Hcl Generic | 20 | 20 | 13 | $113 |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 20 | 20 | Under 11 | $325K |
| Pemetrexed Disodium Generic | 20 | 20 | Under 11 | $24K |
Brand drugs: 504 claims; generic drugs: 588 claims; opioid claims: 40.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kush Sachdeva $2,822 ($2,822 in general payments such as food, travel and fees) from 48 companies. The largest payer was Novartis Pharmaceuticals Corporation with $260.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 13 | $260 |
| GlaxoSmithKline, LLC. GSK | 13 | $205 |
| Daiichi Sankyo Inc. 4568.T | 10 | $185 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $182 |
| Astellas Pharma US Inc 4503.T | 6 | $120 |
| Merck Sharp & Dohme LLC MRK | 6 | $120 |
| Incyte Corporation INCY | 2 | $119 |
| Pfizer Inc. PFE | 9 | $118 |
| Abbvie Inc. ABBV | 7 | $107 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $74.25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.